Michael Kranda | Chief Executive Officer

Mr. Kranda has over 25 years of biotech operating, finance and corporate development experience. Most recently Mr. Kranda was CEO and a director of Vaccinogen, a cancer vaccine company. Mr. Kranda served as Managing Director of Vulcan Capital (Paul Allen’s investment vehicle) for several years, where he led all aspects of their Life Sciences investment efforts and continues to serve as a consultant. Mr. Kranda was also the CEO of Oxford GlycoSciences, a pioneer in proteomic based drug and diagnostic product development. Prior to joining Oxford GlycoSciences, Mr. Kranda was President, COO and director at Immunex Corporation (now Amgen) and is currently a Director for PTC Therapeutics, Inc. (NASDAQ: PTCT) and Chairman of the Audit Committee.

Gregory G. Mahairas, Ph.D. | President & Chief Scientific Officer

Sam Teichman, MD | Chief Medical Officer

Jim Leggett, M.D. | Chairman

Dr. Leggett is the Medical Director of the Diagnostic Vascular Laboratory at Overlake Internal Medicine Associates, and, Medical Director of the Hope Heart Institute. Dr. Leggett received his MD from the University of Arkansas Medical Sciences Center, and his internal medicine and cardiology training at the University of Washington and University of New Mexico School of Medicine respectively. Dr. Leggett is board certified in internal medicine and cardiovascular medicine, and is an expert in the treatment of cardiovascular disease, and non-invasive and invasive techniques to treat coronary and peripheral artery disease.

Michael Regnier, Ph.D.

Scientific co-founder and Scientific Advisory Board Member. Dr. Regnier is Professor and Vice Chairman of the department of Bioengineering at the University of Washington. Dr. Regnier leads the Heart and Muscle Mechanics laboratory in the Department of Bioengineering and is an expert in cardiac and skeletal muscle physiology, muscle dysfunction with disease and development of gene and cell therapies. He is an established Investigator of the American Heart Association, and an Affiliate Investigator of the Benaroya Research Institute. Dr. Regnier holds a Ph.D. in Biology and Neurobiology from the University of Southern California

Craig Tall

Mr. Tall is the managing director of CET Capital Partners LLC, which provides assistance in mergers and acquisitions, financing strategies and other financial matters. Prior to founding CET Capital Partners, he served as Vice Chairman of Washington Mutual Inc. from1999 to 2004 and before that, beginning in 1985, as Executive Vice President of corporate development for Washington Mutual. Earlier in his career he was President and owner of an employee benefits consulting firm. He presently holds board positions for a diverse group of companies, including The Space Needle Corporation, True Blue Inc. (NYSE), Cascadia Capital and Vittana (a not-for-profit global micro student lender). Craig holds a B.S. in Economics from the University of Pennsylvania’s Wharton School.

Chad Waite | (Observer for the WFund)

Mr. Waite joined OVP Venture Partners in 1987 and focuses on investments in the digital biology, and network security sectors. His investments include 4thPass, Accelerator, Adapx, Cardima, CellPro, Complete Genomics, Corixa, Filenet, GenoLogics, Limerick BioPharma, NanoString, Quantum Medical, Raytel Medical, Rosetta Inpharmatics, and Seattle Genetics. He currently serves on the Board of Directors of Accelerator, Adapx, Aggregate Knowledge, NanoString (NSTG), Symform, Talyst, The W Fund and Verdezyne. Prior to joining OVP, Chad was a General Partner at Hambrecht & Quist Venture Partners where he focused on investments in IT and life sciences. Chad received his BA in History from Kenyon College and his MBA from Harvard Business School. He is a Trustee at Kenyon College and has also served as a board member of the NVCA.